Sei Investments Co. Buys 20,581 Shares of Natera, Inc. $NTRA

Sei Investments Co. raised its position in shares of Natera, Inc. (NASDAQ:NTRA) by 11.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 196,833 shares of the medical research company’s stock after purchasing an additional 20,581 shares during the period. Sei Investments Co.’s holdings in Natera were worth $39,366,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Integrated Wealth Concepts LLC raised its stake in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after buying an additional 96 shares during the period. NewEdge Advisors LLC increased its holdings in Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth increased its holdings in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after acquiring an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Natera in the 2nd quarter valued at about $298,000. Finally, WINTON GROUP Ltd bought a new stake in Natera in the 2nd quarter valued at about $558,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of NASDAQ NTRA opened at $261.99 on Monday. The stock’s 50-day simple moving average is $240.75 and its two-hundred day simple moving average is $221.50. The firm has a market capitalization of $37.52 billion, a P/E ratio of -160.73 and a beta of 1.51. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04.

Insider Activity

In other news, Director Rowan E. Chapman sold 2,964 shares of Natera stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the sale, the director directly owned 3,124 shares of the company’s stock, valued at approximately $677,220.72. The trade was a 48.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares of the company’s stock, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 167,171 shares of company stock worth $37,239,209. Corporate insiders own 5.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on NTRA. Barclays reduced their target price on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, June 24th. Wolfe Research assumed coverage on shares of Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Morgan Stanley boosted their target price on shares of Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Guggenheim lifted their price target on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.